Haplotyping and copy number estimation of the highly polymorphic human beta-defensin locus on 8p23 by 454 amplicon sequencing by Taudien, Stefan et al.
Taudien et al. BMC Genomics 2010, 11:252
http://www.biomedcentral.com/1471-2164/11/252
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 Taudien et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Haplotyping and copy number estimation of the 
highly polymorphic human beta-defensin locus on 
8p23 by 454 amplicon sequencing
Stefan Taudien*1, Marco Groth1, Klaus Huse1, Andreas Petzold1, Karol Szafranski1, Jochen Hampe3, Philip Rosenstiel2, 
Stefan Schreiber2,3 and Matthias Platzer1
Abstract
Background: The beta-defensin gene cluster (DEFB) at chromosome 8p23.1 is one of the most copy number (CN) 
variable regions of the human genome. Whereas individual DEFB CNs have been suggested as independent genetic 
risk factors for several diseases (e.g. psoriasis and Crohn's disease), the role of multisite sequence variations (MSV) is less 
well understood and to date has only been reported for prostate cancer. Simultaneous assessment of MSVs and CNs 
can be achieved by PCR, cloning and Sanger sequencing, however, these methods are labour and cost intensive as well 
as prone to methodological bias introduced by bacterial cloning. Here, we demonstrate that amplicon sequencing of 
pooled individual PCR products by the 454 technology allows in-depth determination of MSV haplotypes and 
estimation of DEFB CNs in parallel.
Results: Six PCR products spread over ~87 kb of DEFB and harbouring 24 known MSVs were amplified from 11 DNA 
samples, pooled and sequenced on a Roche 454 GS FLX sequencer. From ~142,000 reads, ~120,000 haplotype calls 
(HC) were inferred that identified 22 haplotypes ranging from 2 to 7 per amplicon. In addition to the 24 known MSVs, 
two additional sequence variations were detected. Minimal CNs were estimated from the ratio of HCs and compared to 
absolute CNs determined by alternative methods. Concordance in CNs was found for 7 samples, the CNs differed by 
one in 2 samples and the estimated minimal CN was half of the absolute in one sample. For 7 samples and 2 amplicons, 
the 454 haplotyping results were compared to those by cloning/Sanger sequencing. Intrinsic problems related to 
chimera formation during PCR and differences between haplotyping by 454 and cloning/Sanger sequencing are 
discussed.
Conclusion: Deep amplicon sequencing using the 454 technology yield thousands of HCs per amplicon for an 
affordable price and may represent an effective method for parallel haplotyping and CN estimation in small to 
medium-sized cohorts. The obtained haplotypes represent a valuable resource to facilitate further studies of the 
biomedical impact of highly CN variable loci such as the beta-defensin locus.
Background
Since the pioneering publication of Margulies et al. [1]
many researchers have demonstrated the versatility of the
massively parallel 454 pyrosequencing technology. The
method has been successfully applied to a large diversity
of targets such as nuclear and organellar genomes [2-4],
transcriptomes [5-8], cloned DNA (e.g. BACs) [9], and
PCR products (amplicons) [10]. This broad spectrum is
complemented by a wide range of analyses, including epi-
genetic features [11,12], genome diversity [13,14] and
ancient DNA [15].
In principle, the 454 technology should also be applica-
ble for haplotyping copy number (CN) variable loci such
as the beta-defensin gene cluster (DEFB) at human chro-
mosome 8p23.1 (Fig. 1). This locus is intensively studied
[16-26] is recognized as one of the most dynamic regions
of the human genome [27] and was proven to be variable
in CN as a whole [28]. Individual DEFB CNs and specific
DEFB haplotypes have been shown to be associated with
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psoriasis, Crohn's disease and prostate cancer
[18,20,29,30]. Within the 2 DEFBs assembled in the
human reference sequence (234 and 224 kb; hg18, build
36.1, chr8:7,156,778-7,391,276 and chr8:7,669,629-
7,893,454), a total of 2,971 single nucleotide polymor-
phisms (SNP) are annotated in dbSNP (build 130) which
we address, more appropriately, as multisite variations
(MSV) [31].
A potential method to assess individual haplotypes at
such loci is the amplification of an MSV-containing
region by PCR [16]. Subsequently, the amplicons are sub-
cloned in plasmids, individual bacterial clones are Sanger
sequenced and haplotypes are determined according to
the bases at the polymorphic positions. This approach,
however, has inherent problems. First, individual CNs
can vary between 2 and 12 DEFB copies per diploid
genome. Theoretically, each genotype can comprise a
number of haplotypes equal to this CN.
For individuals with many copies there is a high risk of
missing rare haplotypes due to the decreased per-copy
sequencing depth of 100-200 reads per genotype in a typ-
ical cloning/Sanger sequencing approach.
Second, PCR on complex templates may result in chi-
mera formation by PCR-mediated recombination, creat-
ing artificial, false-positive haplotypes [32]. Third, the
bacterial cloning step may introduce a systematic bias in
the observed haplotype frequencies due to differences in
the compatibility of clones with the host's lifecycle. To
minimize the risk of spurious haplotyping by PCR/sub-
cloning, independent PCR products have to be analyzed
and large numbers of clones should be sequenced. This
necessary quality control is usually too costly and labour
intensive for high-throughput applications. In addition to
assessing sequence variations, haplotyping has also been
used for the measurement of DEFB CNs [16,17]. Absolute
CNs, however, cannot be determined and even reliable
relative CN measurement by this method is challenging.
E. g. in the simplest case of just 2 copies and 2 haplotypes
in an MSV spanning region, relatively small numerical
deviations from the theoretical ratio of 1.0 (1:1) may
result in quite different minimal CN estimations, as 1.2
(6:5) indicates 11 copies, 1.25 (5:4) indicates 9 and 1.33
(4:3) indicates 7.
For effective and accurate determinations of absolute
DEFB CN, multiplex ligation-dependent probe amplifica-
tion (MLPA) [28,33], real-time PCR [26,34,35], multiplex
amplifiable probe hybridisation combined with restric-
tion enzyme digest variant ratios (MAPH/REDVR) [36]
and different variants of paralog ratio tests (PRT)
[18,28,36] have been applied, however, they do not pro-
vide haplotype information. Knowledge, however, of both
DEFB CN [20,29,30] and haplotypes [18] is of great
Figure 1 Human defensin gene clusters at 8p23.1 (NCBI build 36, hg18) and location of the amplicons analyzed by 454 (F1-8) and cloning/
Sanger (S1-2) sequencing within the proximal DEFB (DEF cluster b2).Taudien et al. BMC Genomics 2010, 11:252
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importance with respect to clinically important pheno-
types. Therefore, an ideal method for DEFB analysis and
association studies would provide both CNs and haplo-
types at once.
Application of massively parallel 454 technology to
PCR amplicons allows extreme in-depth sequencing
resulting from the huge amount of data generated by a
single instrument run. Given a 250 bp amplicon and
assuming 12,000 reads of ~250 bp length per 1/16th seg-
ment of a GS FLX sequencer picotiterplate (GS FLX
amplicon protocol), 16 PCR products can be sequenced
in parallel with 12,000× coverage. This over-sequencing
can be reasonably reduced using a multiplex approach,
pooling either different amplicons generated from the
same DNA [37,38] or the same amplicons derived from
multiple DNAs using a barcoding strategy [39]. However,
in the example above, pooling of 8 amplicons should still
lead to a mean coverage of 1,500. This amount of
sequences per individual amplicon is still sufficient to
reduce the probability for haplotyping errors as described
above. Furthermore, 454 amplicon sequencing does not
require bacterial cloning, avoiding the danger of respec-
tive biases. As result, it delivers a multiple of individual
sequences for a given amplicon compared to a routine
cloning/Sanger sequencing strategy.
We took advantage of this methodological approach for
DEFB haplotyping and CN estimation by 454 sequencing
to study the DEFB locus in 11 DNA samples from pub-
licly available lymphoblastoid cell lines (LCL). The results
are compared to those obtained by the cloning/Sanger
approach, and to CN measurements using MLPA,
MAPH/REDVR and PRT.
Methods
DNA
Genomic DNA from the CEPH Resources (NA12760),
the DNA Polymorphism Discovery Resource Collection
(NA15029, NA15213, and NA15385) and the [40]
(NA18502, NA18552, NA18858, NA19140) were pur-
chased at the Coriell cell depository http://ccr.coriell.org/
. DNAs C0140, C0766 and C0913 were obtained from the
European Collection of Cell Cultures ECACC [41]. All 11
DNAs are derived from human LCLs, which were estab-
lished from individuals of different ancestry, i.e. Cauca-
sian (C0140, C0766, C0913, and NA12760), Yoruba
(NA18502, NA18858, and NA19140) and Han Chinese
(NA18552). For NA15029, NA15213, and NA15385 no
information about the ethnicity of the donors is provided
by the Discovery Resource Collection.
454 amplicon sequencing
PCR methods have been established to generate 8 DEFB
specific amplicons (F1 to F8) using 454 adaptors A and B
containing fusion primers (HPLC purified, TIBMolBio;
Additional file 1, Table S1). PCRs were carried out with
50 ng DNA using the "Advantage" mixed polymerase con-
taining both Taq  and a proofreading enzyme (Clontech
639201) and 35 cycles of 94°C for 30 s, 57°C for 1 min and
72°C for 2 min followed by 72°C for 10 min. Concentra-
tions of the PCR products were measured by Nanodrop
and the Quant-IT® PicoGreen® ds DNA assay (Invitrogen).
All amplicons derived from an individual DNA sample
were mixed in an equimolar ratio (~4 × 1010 molecules
per amplicon). The pools were diluted and subjected to
emulsion PCR following the FLX emPCR protocol for
amplicons (Roche Diagnostics, December 2007) using
both emPCR kits II (primer A) and III (primer B) and
sequenced on a GS FLX (Roche Diagnostics) by both
primers on 1 lane/pool of a 16-lane gasket on a 70 × 75
FLX picotiterplate. The sequences from 1 lane were
aligned to a backbone consisting of the merged PCR tar-
get regions derived from the human reference sequence
(NCBI build 36.1, hg18, proximal gene cluster) and haplo-
type calls (HCs) were inferred using the GS Amplicon
Variant Analyzer Software (Roche Diagnostics).
For verification, amplicon F5 (DEFB4) was generated
from NA12760 and NA18502 by a separate PCR using the
same fusion primers and conditions as described for the
amplicon pools. GS FLX sequencing was done on 2 lanes/
amplicon of a 16-lane gasket on a 70 × 75 picotiterplate.
To further increase sequencing depth, a third GS FLX run
was performed with pooled amplicons F2, F4, F6 and F8
of NA12760, NA18502, NA18552, and NA18858 using a
4-lane gasket on a 70 × 75 picotiterplate. To avoid misin-
terpretations caused by incidental chimera formation
early in PCR, 4 independent reactions were carried out
with each primer pair and DNA sample.
Amplicon subcloning in bacteria and Sanger sequencing
Using 7 out of the 11 DNAs (C0140, C0766, C0913,
NA12760, NA18502, NA18858, NA19140), 2 PCR prod-
ucts (S1 and S2 [16]) were generated using unmodified
primers (Metabion, Additional file 1, Table S1). PCRs
were performed with 50 ng DNA using Taq polymerase
(BIORAD). Amplification was achieved using 5 cycles of
95°C for 30 s, 56°C for 30 s and 72°C for 1 min followed by
30 cycles of 95°C for 30 s, 58°C for 30 s and 72°C for 1
min, and finally 72°C for 5 min. PCR products were sub-
cloned into PCR2.1-TOPO vector (Invitrogen) and 192
individual clones per DNA and amplicon were sequenced
by dye terminator sequencing chemistry using an
ABI3730xl automated sequencer (Applied Biosystems)
and M13rev universal primers. Haplotypes were inferred
by manual inspection of Phrap alignments using GAP4
(Staden package).
Other copy number measurement methods
The pyrosequencing based PRT (PPRT), the MLPA anal-
yses [28] and the 5-PRT [18] were carried out as previ-
ously described. Results of CNs measured by MAPH/Taudien et al. BMC Genomics 2010, 11:252
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REDVR and another PRT [36] were kindly provided by J.
Armour and E. Hollox.
Results
Haplotyping by 454 amplicon sequencing and comparison 
with the cloning/Sanger approach
The amplicons used in the present study were designed in
order to cover a broad spectrum of regions within DEFB
encompassing putative promoters, exons and introns and
i n t e r g e n i c  p a r t s .  I f  p o s s i b l e ,  a m p l i c o n  l e n g t h s  w e r e
restricted to span not much more than 250 bp in order to
obtain consistent haplotype information by 454 reads
from both ends. Furthermore, the amplified regions were
selected to contain a high number of known MSVs.
Application of these criteria resulted in 8 amplicons (F1
to F8) with lengths of 194-340 bp, spread over a region of
87 kb (Fig. 1) and harbouring 32 known MSVs (31 single
nucleotide exchanges and one single base insertion/dele-
tion, dbSNP build 130, Additional file 1, Table S2). Each
amplicon harbours between 2 (F2) and 6 MSVs (F8).
Eleven genomic DNAs were selected to represent a broad
range of CNs as determined by MLPA, that is, 2-9 DEFB
copies per diploid genome. PCRs were performed sepa-
rately for each DNA and primer pair followed by equimo-
lar pooling of all PCR products of the same DNA. For
validation purposes, 2 additional amplicons from 7 sam-
p l e s  w e r e  a n a l y s e d  b y  c l o n i n g / S a n g e r  s e q u e n c i n g  [ 1 6 ]
(S1: 4 MSVs/500 bp, S2: 5 MSVs/529 bp; Fig. 1, Additional
file 1, Table S2).
Eleven lanes of a single GS FLX run (one amplicon pool
per 1/16th plate) resulted in 145,836 reads with an average
length of 225 bp, producing a total of 32.8 Mb raw data.
Of the total reads, 142,033 reads (97.4%) could be assem-
bled to the amplicon reference sequences resulting in an
average of 12,912 reads per DNA sample and 18,230 per
amplicon (Additional file 1, Table S3). Among the ampli-
cons, F1 and F3 were underrepresented by 6,955 and
8,082 reads, respectively, compared to 15,003-24,723 for
the remaining 6 amplicons. Additionally, the amount of
reads per DNA sample greatly differed for F1 and F3 with
less than 100 reads in 4 cases. Therefore, we have
excluded the data of F1 and F3, leaving a total of 126,996
reads from 6 amplicons used for further analyses of the 11
DNA samples.
Every read may be regarded as representation of a par-
ticular DEFB allele. A haplotype can be inferred from
each read by determination of the MSV allele combina-
tion, named "haplotype call" (HC). As amplicons were
designed in accordance with the read length achievable
by the GS FLX chemistry (~250 bp), the small minority of
reads greatly shorter than 250 bp produced by the FLX
sequencing may not span the aspired haplotype. Such
shorter HCs, however, are less informative and would
complicate the analyses. Therefore, these suboptimal
HCs were omitted from further analyses, reducing the
final data set from 126,996 reads to 123,003 most infor-
mative HCs (Additional file 1, Table S4).
Out of the 24 known MSVs within the 6 amplicons, 23
were found to be polymorphic. For rs4840825 (MSV16,
amplicon F7), exclusively the T allele was observed. In
addition, we confirmed in amplicon F5 of C0140,
NA18858 and NA19140 an MSV at position 31 down-
stream of DEFB4  (A/G; chr8:7,259,758 and 7,791,677;
MSV9a) not annotated in dbSNP but present in the hg18
reference sequence as a paralogous sequence variation
[31]. Moreover, we identified a novel base exchange in the
same amplicon of NA18502 located 24 nucleotides fur-
ther downstream (C/A; chr8: 7,259,734 and 7,791,701;
MSV10a).
The MSV combinations in 5 out of 6 amplicons could
be unambiguously deduced from the overlapping forward
and reverse reads. However, for F5 (340 bp, MSVs 6-10a)
the read length of the FLX chemistry was too short to
directly infer complete haplotypes, as the forward reads
cover MSVs 6-8 and the reverse reads 7-10a, respectively
(Table 1). Nevertheless, using data from non-polymor-
phic samples, the HC ratios in polymorphic samples and
a parsimony assumption, 4 forward and 7 reverse haplo-
types collapse consistently into 7 complete F5 haplotypes
(Additional file 1, Table S5).
In total, 22 haplotypes could be identified (Table 1,
Additional file 1, Table S5). The largest variety was found
for amplicon F5 with 7 haplotypes out of 128 theoretically
possible combinations of MSVs. In contrast, only 2 haplo-
types were observed for F7 (8 theoretical haplotypes) and
F8 (64), respectively. The most abundant haplotypes are
for F2: GA, F4: TAC, F5: TCCGGGC, F6: CCTCG, F7:
TCG and F8: CTACCG,. TCCGGGC and TCG were
found in all investigated DNAs. Joining the haplotypes
with the most HCs for each DNA sample individually cre-
ates 4 inferred "long range haplotypes" of which one is
present in of 6 samples (Additional file 1, Table S6).
Remarkably, this inferred haplotype can be generated by
just one recombination of physical haplotypes repre-
sented by large insert clones from the RPCI-11 Human
Male BAC Library, sequenced in the course of the human
genome project [16] (Fig. 2).
Several additional MSV combinations were found
which are represented by only few reads compared to the
haplotypes described above, indicating either the genera-
tion of chimeric, PCR-mediated recombinant molecules
from different target copies, misincorporations during
the emulsion PCR, sequencing errors or cross-contami-
nations. In total, 53 out of 66 454 PCRs and 10 out of 22
Sanger PCRs contained this phenomenon. Based on the
estimation by alternative methods that the maximal
DEFB CN in our sample set is 9, we discarded HCs with
fractions <0.10 (1/10) as such artefacts. This led to theT
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Table 1: Haplotype calls from 454 (run 1) and cloning/Sanger (CS) sequencing.
Method 454 CS 454 CS 454 CS 454 454 454 454 454 CS
Amplicon F2 S1 F5 S2 F5 S2 F4 F6 F7 F8 Total
MSV HCs 1-2 # # 6-8 # # 7-10a* # # 3-5 # 11-15 # 16-18 # 19-24 # HCs #
C0140 GA 1.566 112 TCC 664 136 CCGgGc 1.491 81 TAT 582 CCTCG 867 TCG 888 CTACCG 542
GG 583 36 CCGaGc 431 55 CAT 390 CCTAG 816 TTA 288 TCTTTA 195
CA 528 30 TAC 382 10.213 450
C0766 GG 1.525 114 TCC 360 140 CCGgGc 1.084 147 TAC 1.679 nd TCG 1.878 CTACCG 876
CA 842 41 CCC 195 48 CCGgAc 506 41 CAT 601 9.546 531
C0913 CA 1.869 113 TCC 680 132 CCGgGc 1.221 145 TAC 1.556 CCTCG 1.195 TCG 1.816 CTACCG 2.153
GA 1.157 58 CCC 287 54 CCGgAc 617 41 TCC 634 CCTAG 593 13.778 543
NA12760 GA 1.750 92 TCC 795 99 CCGgGc 1.566 104 TAC 2.825 CCTCG 1.669 TTA 2.056 TCTTTA 645
GG 386 20 CCC 181 60 CCGgAc 339 55 TAT 981 CTCAC 599 TCG 1.696 CTACCG 605
CA 319 19 CTG 184 0 TGGgAc 459 0 TCC 797 CCTAG 499 18.351 449
NA15029 GA 1.530 TCC 767 nd CCGgGc 1.046 nd TCC 1.156 CCTGC 1.785 TTA 1.689 TCTTTA 377
GG 805 CCAgGc 431 TAT 882 CTCAT 1.087 TCG 1.115 CTACCG 267
CTG 475 TGGgAc 913 TAC 496
CAT 420 15.241
NA15213 GA 1.326 TCC 665 nd CCGgGc 1.338 nd TAC 278 CCTCG 1.178 TCG 1.496 CTACCG 929
CA 349 CTG 171 TGGgAc 390 TAT 98 CCTAG 577 TTA 866 TCTTTA 551
TCC 87 CTCAT 473 10.772
NA15385 GA 985 TCC 374 nd CCGgGc 702 nd TAC 1.374 CCTCG 1.003 TCG 938 CTACCG 688
GG 592 CCC 169 CCGgAc 239 TAT 673 CCTAG 322 TTA 782 TCTTTA 483
CTG 88 TGGgAc 188 TCC 345 CTCAT 280 10.225
NA18502 GA 812 80 TCC 182 125 CCGgGc 265 139 TAT 1.453 CCTCG 415 TTA 856 TCTTTA 645T
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CA 561 58 CCC 21 15 CCGgGa 56 0 TTCAT 65 TCG 418 CTACCG 267
CCG (7) 0 CGGgAc 39 0 5.995 402
NA18552 CA 3.490 TCC 197 nd CCGgGc 273 nd TAT 225 CCTCG 1.653 TCG 1.756 CTACCG 1.525
CCC 328 CCGgAc 340 TAC 1.058
CAT 503 11.348
NA18858 GA 677 97 TCC 1.234 188 CCGgGc 623 124 TAT 1.490 CCTCG 1.327 TTA 1.087 TCTTTA 2.404
CA 324 45 CCGaGc 218 51 TAC 822 TCG 404 CTACCG 633
GG 205 (16) 11.448 505
NA19140 GA 314 57 TCC 706 nd CCGgGc 234 nd nd CCTCG 504 TTA 281 nd
CA 310 73 CCGaGc 42 CTCAT 130 TCG 62
GG 105 24 2.688 154
Total 22.910 1.069 8.702 982 15.012 983 21.787 17.03
7
20.372 13.785 119.605 3.03
4
#: number of HCs; *: alleles in lower cases refer to the 2 additionally identified MSVs 9a and 10a; (): nominally below 10% threshold; nd: no data.
Table 1: Haplotype calls from 454 (run 1) and cloning/Sanger (CS) sequencing. (Continued)Taudien et al. BMC Genomics 2010, 11:252
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exclusion of 3,338 (2.7%) and 86 (2.7%) HCs from the 454
and Sanger datasets, respectively (Table 1, Additional file
1, Table S4).
Comparing the haplotyping results for both methods,
the same haplotypes were found in 85% (11/13) except for
amplicons F5/S2 in samples NA12760 and NA18502
(Table 1). In both cases rare 454 haplotypes were not
found in the Sanger reads. Due to the low overall number
of F5 sequences for NA18502, the HC frequency for the
haplotype inferred from MSVs 6-8 is lower <0.10 and had
to be excluded (Table 1, value in brackets; Additional file
1, Table S4). In order to finally confirm or reject the ques-
tionable haplotypes, we generated additional F5 ampli-
cons from the 2 DNA samples and performed 454
sequencing in 2/16th plate per sample resulting in 33,305
and 33,205 sequences, respectively. From these reads
more than 10,000 HCs per sample for MSVs 6-8 and over
20,000 calls for MSVs 7-10a were obtained for each of the
2 DNAs, unequivocally confirming the presence of the
questionable CTGGGAC and CCGGGAC haplotypes,
respectively (Table 2).
Determination of relative DEFB copy numbers by 
haplotype calls
In order to evaluate the applicability of 454 HCs for the
measurement of relative DEFB CNs, we calculated the
HC ratios for all amplicons with more than one haplotype
and inferred the respective minimal CN. For example, in
F2 from C0140, 3 haplotypes (CA, GA, and GG) were
identified with 528, 1,566 and 583 calls, respectively. This
corresponds to a normalized call ratio of 1:2.97:1.10 that
is essentially 1:3:1, indicating a minimal CN of 5. Alto-
gether, by this approach 60 CN calculations were done.
For samples with more than one polymorphic amplicon
we computed the average of the separate CNs or of their
least common multiple. The final minimal CN estima-
tions for the samples range between 3 and 9 (Table 3,
Additional file 1, Table S7).
The DEFB CNs of the 11 samples haplotyped in this
study were previously measured by 40 independent
experiments using different PRTs, MLPA and MAPH/
REDVR [18,28,36] and Armour and Hollox, personal
communication]. For 8 of the 11 DNAs, measurement by
the different techniques (not including our) resulted in
identical CNs. The remaining samples showed disagree-
ments of only one copy, indicating the consistency of the
data (Table 3, Additional file 1, Table S7). Therefore, we
took the average of these measurements and compared
them with CN estimates from the 454 HCs. For 7 samples
the 454 haplotype-based estimates were in agreement
with CNs determined by the alternative methods. For
another 2 DNA samples (NA15213, NA15385), these
Figure 2 Comparison of physical long range DEFB haplotypes derived from RPCI-11 Human Male BAC sequences (HT 1-3) and HC inferred 
long range haplotypes (HT A-D). Underline: relation of haplotypes 2, 3 and A; gray: additional observed amplicon haplotypes indicating that all BAC 
specific patterns are also present in the 11 analyzed samples.Taudien et al. BMC Genomics 2010, 11:252
http://www.biomedcentral.com/1471-2164/11/252
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numbers differed only by one copy. In the case of
NA18858, the estimated minimal CN was half of the
absolute one. For NA18552, 3 MSV combinations are
polymorphic, resulting in CNs of 5 (2:3), 2n (1:1) and 7
(2:4:1), respectively. Only in this single case, the HC-
based minimal CN estimations can not be unambigu-
ously interpreted and considerably deviates from 2 copies
per diploid genome, consistently determined by 4 alter-
native methods.
As ultra-deep sequencing of NA12760 and NA18502
amplicon F5 provided most consistent CN estimations
(Table 2, Additional file 1, Table S7) for samples with high
CNs, we further validated this approach by performing a
third GS FLX run with pooled amplicons F2, F4, F6 and
F8 from these DNAs. Moreover, we included NA18552
(CN = 7 by HCs of amplicons F4) and NA18858 (CN = 8
by alternative methods) (Table 3). To avoid false positive
HCs resulting from chimera formation early in PCR, we
carried out 4 independent reactions with each primer
pair and DNA sample. Accordingly, we lowered the
threshold for exclusion of minor haplotype fractions from
10% to 6% to avoid false negative HCs. Altogether, we
obtained 405,574 HCs providing on average ~25,000 per
amplicon and sample (Additional file 1, Table S8), of
which 1.4% were excluded as potential chimera, sequenc-
ing errors or contaminations. The extraordinary sequenc-
ing depth and the lowered filter threshold identified
additional haplotypes for NA18502 (F2: GG) and
NA18858 (F4: CAT, F6: TTCAT) which increased the res-
olution of the CN estimation (Table 4, Additional file 1,
Table S9). Ultra-deep sequencing-based CN estimations
for samples with high CNs (NA18502, NA18858) tend to
be higher than those determined by the established alter-
native methods.
Discussion
Impaired beta-defensin synthesis has been described in
many human diseased states, namely in inflammatory
disorders [20,22,29,30,42-44]. While association of a dis-
ease and DEFB CN has been demonstrated [20,29,30],
associations of sequence variants with disease [18] can-
not reliably be investigated with established genotyping
methods. Hollox [22] observed that it may be the nucle-
otide state of an MSV that actually causes susceptibility to
a disease for which association with CN has been found.
If so, CN is only a proxy for causative sequence variants.
However, description of sequence variation in CN vari-
able loci such as DEFB at 8p23 is inherently challenging.
Currently, neither the haplotype structure of DEFBs nor
their arrangements on chromosomes (DEFB-locus
alleles) are known. The present work provides a first
glimpse of the DEFB haplotype complexity through 454
amplicon sequencing of selected polymorphic defensin
gene fragments. Among the currently available next gen-
eration sequencing (NGS) approaches, the 454 technol-
ogy is best suited for this purpose as it provides longest
reads that in turn produce the longest inferred physical
haplotypes.
Eleven DNA samples derived from LCLs were selected
to represent a range of 2-9 DEFB copies per diploid
genome. All DNAs are publicly available and 4 were
investigated in the framework of the HapMap project
[40]. Four of the LCLs were established from individuals
of Caucasian, 3 of Yoruba and one of Chinese ancestry.
About 120,000 MSV HCs were derived from 6 amplicons
containing 2-6 annotated MSVs each. One MSV not
deposited in dbSNP and a new one were detected in 3
samples of Yoruba and one of Caucasian ancestry, respec-
tively. Theoretically, the 26 MSVs in 6 amplicons alto-
Table 2: Haplotype calls of ultra-deep amplicon F5 454 sequencing (run 2) for NA12760 and NA18502.
F5 forward F5 reverse
MSV HCs 6-8 # f 7-10a* # f
NA12760 TCC 7.399 0,69 CCGgGc 14.683 0,72
CCC 1.765 0,16 CCGgAc 2.891 0,14
CTG 1.591 0,15 TGGgAc 2.895 0,14
Total 10.755 20.469
NA18502 TCC 8.307 0,80 CCGgGc 17.586 0,83
CCC 1.069 0,10 CCGgGa 1.764 0,08
CCG 1.006 0,10 CGGgAc 1.950 0,09
Total 10.382 21.300
#: number of HCs; f = HC frequency; *: alleles in lower cases refer to the 2 additionally identified MSVs 9a and 10a.T
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Table 3: DEFB copy numbers per diploid genome estimated by the ratio of 454 haplotype calls (run 1) in comparison to alternative methods.
454 Alternative methods
Amplicon F2 F5f F5r F4 F6 F7 F8 Average Armour 5PRT PPRT MLPA Average 454-Altern.
MSVs 1-2 6-8 7-10a 3-5 11-15 16-18 19-24 ~ ~ ~
C0140 5 4 4 (2n) 4 4 4.20 4 4 3.78 4.19 4 3.99 40
C0766 3 3 3 4 3.25 3 3 2.75 3.31 3 3.01 30
C0913 33 3 3 3 3 . 0 0 3 3 3.00 3.13 3 3.03 30
NA12760 7 6 6 6 5 6 (2n) 6 (2n) 6.00 6 6 5.57 6.04 6 5.90 60
NA15029 6  ( 3 n ) 556555 5 . 2 9 5 nd 4.70 5.58 5 5.09 50
NA15213 5 545455 4 . 7 1 5 nd 4.18 4.18 4 4.12 4+ 1
NA15385 57 5 7 5 6  ( 2 n ) 5 5 . 7 1 6 nd 5.29 5.17 5 5.15 5+ 1
NA18502 10 10 9 7 9 (3n) 8 (4n) 8.83 9 8 8.98 nd 9 8.66 90
NA18552 56  ( 2 n )7 6 . 0 0 6 2 2.23 2.02 2 2.06 2+ 4
NA18858 44 3 4 5 4 . 0 0 4 8 7.71 8.08 8 7.95 8- 4
NA19140 7 7 5 6 6.25 6 7 5.71 6.26 6 6.24 60
Armour: PRT and MAPH/REDVR [36] and personal communication; 5PRT. PPRT [18,28]; MLPA [28]. ~: rounded; n: multiple of the minimal estimated CN; *: CN estimations based on ultra-deep 454 
sequencing; nd: no data; blank: non polymorphic.Taudien et al. BMC Genomics 2010, 11:252
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gether could compose 268 haplotypes of which we
identified 22 (8%). As exemplified by the analysis of the
F5 amplicon data, HC ratios provided by the 454 deep
sequencing approach may serve as additional experimen-
tal evidence to deduce longer haplotypes than the maxi-
mal NGS read length.
With 26 MSVs in 6 amplicons, totalling to 1,498 bp, the
MSV density in the investigated regions is approximately
17 MSV/kb. This is higher than the overall single nucle-
otide variation density of the entire DEFB currently anno-
tated in dbSNP (2,971 MSVs/229 kb = 13 MSV/kb) and
reflects the directed selection of the amplified regions to
screen a maximum of polymorphic positions within a
short distance. In comparison, for the most sequence
variable locus of the human genome, the MHC complex,
alignments of 8 MHC haplotypes revealed 8 SNP/kb
(37,451 SNPs/4.7 Mb) with a higher density (13 SNP/kb)
in the intragenic regions [45]. For the genomic loci of
HLA-A, B and C there are 1,578 polymorphic positions
within 10,020 bp assigned by dbSNP build 130, corre-
sponding to 157 SNPs/kb. This indicates that in terms of
sequence variability, DEFB is substantially less polymor-
phic than the HLA loci, and that DEFB together with the
analysed amplicons are comparable to the MHC
intragenic regions. The fact that the 454 deep-sequencing
revealed only one novel MSV on the background of 24
previously known ones shows that the dbSNP annotation
of the analysed regions is quite comprehensive. On the
other hand according to dbSNP, the MSV density of
DEFB is about 4 times higher than the SNP density of the
entire human genome (4 SNP/kb). Moreover, currently
unknown additional sequence variability may be still hid-
den in the DEFB (e.g. 25 MSV/kb upstream of DEFB4
observed in 16 LCLs; Groth, unpublished) which may be
revealed by future targeted and whole-genome rese-
quencing efforts.
The haplotypes identified by 454 sequencing and by
cloning/Sanger sequencing were identical except for 2
cases, which could be resolved by additional 454
sequencing. However, the ratios of haplotypes derived
from a given individual amplicon sometimes differ
remarkably. For example, the C0913 F5 haplotypes CCG-
GAC and CCCGGC were revealed by 454 sequencing in a
ratio of 1:2 (617/1,221 calls) but 1:3.5 (41/145 calls) by
Sanger derived reads. We suspect the explanation is that
the number of HCs from Sanger sequenced clones is too
low for providing reliable results. Moreover, additional
bias may be introduced e.g. by the bacterial cloning step.
Theoretically, the more HCs that are available, the
more accurately they should reflect the real ratio of the
DEFB copies with particular haplotypes. This becomes
more important as the number of DEFBs and/or haplo-
types per genome increases. The conclusion is supported
by our efforts to resolve the discrepancies between 454
and Sanger sequencing for NA12760 and NA18502. The
minor haplotypes of the F5 amplicon were supported by
454 but not by Sanger sequencing, probably due to the
low amount of sequenced clones. Additional 454 HCs
finally confirmed the presence of the F5 haplotypes under
question.
Furthermore we noticed an uneven distribution of for-
ward and reverse reads in the 454 sequencing of particu-
lar amplicons. This is obvious in Fig. 3 with a nearly 1:2
forward-to-reverse read ratio and is also reflected in the
entire data set of amplicon F5 with 8,702 forward but
15,020 reverse HCs (1:1.7). Such a skew may be caused by
unequal sequencing efficiencies due to the direction-spe-
cific sequencing primers as well as to differences in base
composition and/or motifs between the forward and
reverse strands. Thus in the case of non or partially over-
lapping forward and reverse reads, the resolution of the
approach is limited by the less effective sequencing direc-
tion [46,47].
Another problem of any PCR-based haplotyping is the
occurrence of chimeric products [32]. Since both 454
amplicon sequencing and the cloning/Sanger approach
are based on PCR, the formation of such artefacts must
be taken into account. Chimeras can be generated during
Table 4: DEFB copy numbers per diploid genome estimated by 454 ultra-deep sequencing (run 2: F5; run 3: F2, F4, F6, F8) 
in comparison to alternative methods.
454 Alternative 
methods
454-Altern.
Amplicon F2 F5f F5r F4 F6 F8 Average Average
NA12760 8 77759 7 6 +1
NA18502 11 10 11 9 10 10 9 +1
NA18552 nd nd 8 8 2 +6
NA18858 10 nd nd 12 11 10 11 8 +3
nd: no data; blank: non polymorphic.Taudien et al. BMC Genomics 2010, 11:252
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PCR by heteroduplexes of e.g. a complete copy of one
allele with a fragment from another allele. Completion of
the partial strand in the elongation step creates chimeric
molecules from which chimeric haplotypes may be erro-
neously determined. The degree of chimera formation is
dependent on various factors such as polymerase, nucle-
otide/primer concentrations, cycling conditions and
amplicon length. In addition to the formation of chimeric
PCR products, nucleotide misincorporations during the
emulsion PCR, sequencing errors and cross-contamina-
tions have to be taken into account. In the current study,
we have appointed and discarded an MSV combination
as artificial if its relative number of call was lower than
10% (1/10; cloning/Sanger and GS FLX run 1) or 6% (1/
16; ultra-deep FLX runs 2 and 3). This led to the exclu-
sion of less than 3% of all HCs which otherwise would
render the analysis impossible. False negative HCs by this
cutoff per definitionem would only affect DNA samples
with more than 10 and 16 DEFB copies, respectively. CNs
>10 are rarely reported in the literature [23,29,30]. Never-
theless, these threshold filters may fail if the artificial
molecule appears early in PCR. To avoid respective mis-
interpretations, independent PCRs were carried out and
pooled before sequencing for the third GS FLX run.
The estimation of CNs from the HC ratios is intrinsi-
cally problematic, since ratios provide only minimal CNs
and any multiple of that can be ruled out only by addi-
tional considerations (NA18858). Moreover, slightly dif-
ferent ratios lead to different CN estimations.
Nevertheless, thanks to the high number of NGS HCs,
CNs could be correctly determined for 7 out of 11 sam-
ples and differed only by one copy per diploid genome for
another 2 samples (Table 3, Additional file 1, Table S7).
Remarkably, the high HC numbers obtained by ultra-
deep GS FLX runs 2 and 3 consistently point towards
higher CNs than obtained by the widely used PRTs/
MPLA (T ab. 4, Additional file 1, T able S9). It is known
that the latter methods tend to underestimate the actual
CN in case of DEFB CNs >5 (Huse, unpublished). Thus, it
has to be proven in the future, whether ultra-deep NGS
like 454 may provide more reliable results than the cur-
rently established methods for cases of high CNs per dip-
loid genome. The recently developed mrFAST (micro-
read fast alignment search tool) [48] points in the same
direction although the sequencing depth of personalized
whole-genome sequencing efforts and the 1000 Genomes
Project is too low to provide sufficient read counts for
reliable estimations of high CNs in complex regions like
DEFB.
Only in one case were the CN estimations inconsistent
(NA18552: 5-8 copies by 454 sequencing vs. 2 copies by 4
alternative methods, Tables 3 and 4). For this, we suppose
2 possible reasons. First, the estimated CN 5 results from
amplicon F5 with a relatively low amount of reads which
Figure 3 Graphical output of the GS Amplicon Variant Analyzer for the assembly of sequences as exemplarily shown for NA15029, ampli-
con F5. Left Y-axis: minor allele frequency; MSV colour code: blue = C; red = T; black = G; green = A; asterisk: insertion/deletion 454 sequencing artefact 
within a poly-A stretch; blue curve: read coverage; grey bar below: average lengths of forward and reverse reads, respectively.Taudien et al. BMC Genomics 2010, 11:252
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in case of the forward sequencing direction (MSVs 6-8)
caused a random deviation from the 1:1 ratio observed
for the reverse HCs. Second, 7-8 copies were calculated
by the ratio of 3 haplotypes in amplicon F4. As the 3 hap-
lotypes were confirmed by ultra-deep sequencing of
pooled independent amplicons, it is unlikely that the
minor haplotype (TAT) is a chimera. As the remaining
454 amplicons show no sequence variation and are there-
fore in agreement with the low CN of 2 determined by the
alternative methods, sample NA18552 may represent in
our hands the first example violating the concordance
rule of DEFB [28]. Whether the underlying molecular
event represents a natural polymorphism or emerged in
cell culture remains to be elucidated in the future.
Although our results indicate that NGS based haplo-
typing and CN estimation thereof is a suitable approach
to characterize a highly polymorphic and CN variable
loci as the DEFB cluster, this method has some inherent
limitations. First, haplotyping is restricted to those
regions in which at least two MSVs are located within the
read length of the applied NGS technology. Second,
equimolar pooling of PCR products is difficult and also
the efficiencies of the following emulsion PCR may devi-
ate among the amplicons. This can result in differing
amounts of HCs per amplicon which may prevent reliable
haplotyping if too few sequences are obtained (e.g. from
our amplicons F1 and F3). Third, formation of PCR arte-
facts leading to the identification of "false", i.e. chimeric
ha plot ypes a lwa ys  has t o be  c ons ide r ed.  Alt hou gh dis-
tinction between "true" and "false" halpotypes is easier
with higher sequencing depth it is problematic for sam-
ples with high CNs.
Conclusion
Deep 454 amplicon sequencing is an effective method for
parallel haplotyping and CN estimation in highly poly-
morphic loci such as DEFB at chromosome 8p23.1 for the
following reasons:
1. There is no bacterial cloning bias as a source of puta-
tive errors in haplotype identification. Moreover, in con-
trast to the cloning/Sanger sequencing approach,
thousands of HCs per amplicon can easily be performed
leading to a higher accuracy in obtained haplotype ratios
and CN estimations inferred thereof.
2. Calculated on the basis of the consumable's prices for
the present study and normalized to the same yield of
informative HCs, the costs for 454 amplicon sequencing
amounts to only ~4% of those for cloning/Sanger
sequencing. Although this does not even consider the
reduced experimental effort it is still too expensive for
high-throughput measurements but acceptable for analy-
ses of small cohorts.
3. Recently, 454 Titanium amplicon sequencing proto-
cols and kits became available (Roche Diagnostics),
increasing achievable read lengths to 400 bp with a 2-fold
increase of the number of reads per run. Thus, longer
amplicons than in our study can be sequenced, encom-
passing more or more distant MSVs. Moreover, as the
output of reads also increases, multiplexing different
DNAs will be feasible by application of barcoding strate-
gies (multiplex identifier, MID).
4. Although the presented 454 amplicon sequencing
delivers only relative CNs and has to be completed by
other approaches, future inclusion of reference amplicons
from loci with invariable CN will provide absolute DEFB
CNs.
Deep 454 amplicon sequencing can contribute substan-
tially to investigate sequence variants and haplotype
structure of CN variable loci. Nevertheless, increases in
both NGS read length and output are needed to eventu-
ally completely resolve loci like DEFB at the physical hap-
lotype level.
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